Karol Wielgus
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karol Wielgus has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Grzegorz Łyko
Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland
6 shared publications - Maria Antos
Collegium Medicum, Jan Długosz University, Armii Krajowej 13/15, 42-200 Częstochowa, Poland
6 shared publications - Maria Pawłowska
Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland
6 shared publications - Angelika Wawryszuk
Uniwersytet Jana Kochanowskiego w Kielcach
5 shared publications - Jan Ramian
Faculty of Medical Sciences in Katowice, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland
5 shared publications - Adrian Bobrzyk
Śląska Wyższa Szkoła Medyczna w Katowicach
4 shared publications
Latest Publications
- 3 September 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (4)
THE ROLE OF CORTISOL IN THE ETIOLOGY AND TREATMENT OF BRUXISM
Bruxism is an issue that has a major influence on both dental and general health. It is defined by the involuntary clenching and grinding of the teeth. Bruxism can present itself in two main ways: during sleep and during wakefulness. This study investigates the function of the stress hormone cortisol in the development and treatment of bruxism. Those who have bruxism often have elevated cortisol levels, which suggests a strong correlation between stress and bruxism episodes. The study examines the body of research, emphasizing the link between bruxism and hormone changes brought on by stress. It also looks at possible cortisol-management-based therapeutic approaches. Pharmacological therapy, lifestyle adjustments, and stress management strategies are examples of effective interventions. Comprehending the intricate relationship between bruxism and cortisol will aid medical professionals in creating all-encompassing therapy strategies that can ultimately enhance patient results and quality of life.
- 3 September 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (4)
THE ROLE OF CORTISOL IN THE ETIOLOGY AND TREATMENT OF BRUXISM
Bruxism is an issue that has a major influence on both dental and general health. It is defined by the involuntary clenching and grinding of the teeth. Bruxism can present itself in two main ways: during sleep and during wakefulness. This study investigates the function of the stress hormone cortisol in the development and treatment of bruxism. Those who have bruxism often have elevated cortisol levels, which suggests a strong correlation between stress and bruxism episodes. The study examines the body of research, emphasizing the link between bruxism and hormone changes brought on by stress. It also looks at possible cortisol-management-based therapeutic approaches. Pharmacological therapy, lifestyle adjustments, and stress management strategies are examples of effective interventions. Comprehending the intricate relationship between bruxism and cortisol will aid medical professionals in creating all-encompassing therapy strategies that can ultimately enhance patient results and quality of life.
- 3 September 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (4)
ADVANCES IN DIAGNOSIS AND TREATMENT OF CONGENITAL HEART DISEASE: A COMPREHENSIVE REVIEW
The purpose of this article is to provide a comprehensive review of recent advances in the diagnosis and treatment of congenital heart disease (CHD). CHD, which affects about 1% of live births worldwide, is still a major problem in pediatric cardiology. The most prevalent congenital cardiac defects—Ventricular Septal Defect (VSD), Tetralogy of Fallot (TOF), Coronary Artery Fistula, Coarctation of the Aorta (CoA), Aortic and Pulmonary Stenosis, Valve Insufficiency, Double Outlet Right Ventricle (DORV), Ebstein Anomaly, Transposition of the Great Arteries (TGA), Anomalous Venous Return, and Hypoplastic Left Heart Syndrome (HLHS) are all thoroughly examined in this review. The review examines current diagnostic and treatment strategies, highlighting the benefits, drawbacks, sensitivity, and specificity of several imaging modalities, including as CT, MRI, and echocardiography. It also discusses the historical evolution of treatment outcomes, emphasizing the tremendous advances in patient care and surgical procedures that have significantly mproved survival rates and quality of life for CHD patients.
- 3 September 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (4)
ADVANCES IN DIAGNOSIS AND TREATMENT OF CONGENITAL HEART DISEASE: A COMPREHENSIVE REVIEW
The purpose of this article is to provide a comprehensive review of recent advances in the diagnosis and treatment of congenital heart disease (CHD). CHD, which affects about 1% of live births worldwide, is still a major problem in pediatric cardiology. The most prevalent congenital cardiac defects—Ventricular Septal Defect (VSD), Tetralogy of Fallot (TOF), Coronary Artery Fistula, Coarctation of the Aorta (CoA), Aortic and Pulmonary Stenosis, Valve Insufficiency, Double Outlet Right Ventricle (DORV), Ebstein Anomaly, Transposition of the Great Arteries (TGA), Anomalous Venous Return, and Hypoplastic Left Heart Syndrome (HLHS) are all thoroughly examined in this review. The review examines current diagnostic and treatment strategies, highlighting the benefits, drawbacks, sensitivity, and specificity of several imaging modalities, including as CT, MRI, and echocardiography. It also discusses the historical evolution of treatment outcomes, emphasizing the tremendous advances in patient care and surgical procedures that have significantly mproved survival rates and quality of life for CHD patients.
- 1 July 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (3)
CARDIOPROTECTIVE PROPERTIES OF SGLT2-INHIBITORS
Due to its high mortality rate, heart failure (HF) presents a substantial worldwide health burden that calls for efficient treatment approaches. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become essential treatments for heart failure in all left ventricular ejection fraction (LVEF) levels. Their processes, which include enhanced metabolic efficiency and ventricular loading circumstances, present encouraging results. The effectiveness of SGLT2 inhibitors, dapagliflozin and empagliflozin, in lowering cardiovascular mortality and heart failure hospitalizations in heart failure patients with reduced, mildly reduced, and preserved ejection fraction has been shown in several clinical trials, including DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER. These results represent a revolutionary development in the treatment of HF, emphasizing the use of SGLT2 inhibitors in comprehensive treatments, regardless of renal function or diabetes state.
- 1 July 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (3)
CARDIOPROTECTIVE PROPERTIES OF SGLT2-INHIBITORS
Due to its high mortality rate, heart failure (HF) presents a substantial worldwide health burden that calls for efficient treatment approaches. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become essential treatments for heart failure in all left ventricular ejection fraction (LVEF) levels. Their processes, which include enhanced metabolic efficiency and ventricular loading circumstances, present encouraging results. The effectiveness of SGLT2 inhibitors, dapagliflozin and empagliflozin, in lowering cardiovascular mortality and heart failure hospitalizations in heart failure patients with reduced, mildly reduced, and preserved ejection fraction has been shown in several clinical trials, including DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER. These results represent a revolutionary development in the treatment of HF, emphasizing the use of SGLT2 inhibitors in comprehensive treatments, regardless of renal function or diabetes state.
- Open Access
- 25 June 2024
- Published by Termedia Sp. z.o.o. in Polish Journal of Radiology
- Vol. 89, 302-307
Major aortopulmonary collateral arteries: clinical, echocardiographic, and radiologic characteristics
Purpose: Major aortopulmonary collateral arteries (MAPCAs) are rare congenital anomalies with significant clinical implications, often associated with congenital heart diseases like tetralogy of Fallot (TOF) and pulmonary atresia (PA). This study aimed to investigate the clinical, echocardiographic, and radiologic characteristics of MAPCAs in patients with congenital heart diseases admitted to our clinic between 2016 and 2023.Material and methods: A retrospective analysis of 46 cases was conducted using chest computed tomography exams performed on a dual-source 128-slice CT scanner. Clinical data and radiologic characteristics were collected and analysed.Results: The study revealed a strong correlation between congenital heart diseases and the presence of MAPCAs, with TOF, PA, and ventricular septal defect (VSD) being the most common, and it indicated that these collaterals may exist with non-diagnosed congenital heart disease. Tricuspid regurgitation and aortic insufficiency were the predominant echocardiographic findings. Radiologically, MAPCAs primarily originated from the descending aorta (type II) in 85% of cases, and their sizes ranged from ≤ 3 mm to > 10 mm, with an average of 5 mm.Conclusions: This study provides comprehensive insights into the clinical and radiologic aspects of MAPCAs in patients with congenital heart diseases. The findings emphasise the importance of early detection and intervention for better managing of these complex conditions and the need for further research.
- 25 June 2024
- Published by Termedia Sp. z.o.o. in Polish Journal of Radiology
- Vol. 89, 302-307
Open AccessMajor aortopulmonary collateral arteries: clinical, echocardiographic, and radiologic characteristics
Purpose: Major aortopulmonary collateral arteries (MAPCAs) are rare congenital anomalies with significant clinical implications, often associated with congenital heart diseases like tetralogy of Fallot (TOF) and pulmonary atresia (PA). This study aimed to investigate the clinical, echocardiographic, and radiologic characteristics of MAPCAs in patients with congenital heart diseases admitted to our clinic between 2016 and 2023.Material and methods: A retrospective analysis of 46 cases was conducted using chest computed tomography exams performed on a dual-source 128-slice CT scanner. Clinical data and radiologic characteristics were collected and analysed.Results: The study revealed a strong correlation between congenital heart diseases and the presence of MAPCAs, with TOF, PA, and ventricular septal defect (VSD) being the most common, and it indicated that these collaterals may exist with non-diagnosed congenital heart disease. Tricuspid regurgitation and aortic insufficiency were the predominant echocardiographic findings. Radiologically, MAPCAs primarily originated from the descending aorta (type II) in 85% of cases, and their sizes ranged from ≤ 3 mm to > 10 mm, with an average of 5 mm.Conclusions: This study provides comprehensive insights into the clinical and radiologic aspects of MAPCAs in patients with congenital heart diseases. The findings emphasise the importance of early detection and intervention for better managing of these complex conditions and the need for further research.
- Open Access
- 22 May 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 71, 49418
SGLT2-Inhibitors - significant role in Heart Failure treatment
Heart failure (HF), which has a high morbidity and mortality rate, is nevertheless a common and crippling ailment, especially in older populations. The complicated pathophysiology of heart failure (HF), which includes oxidative stress, endothelial dysfunction, fibrosis, and inflammation, is frequently not sufficiently treated despite advances in medication. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become a key treatment for HF in patients with varying left ventricular ejection fractions (LVEF). SGLT2 inhibitors have been shown in recent clinical trials to considerably lower hospitalization rates for heart failure, cardiovascular mortality, and all-cause mortality. The mechanisms of SGLT2 inhibitors, such as better ventricular loading, increased heart metabolic efficiency, and decreased inflammation and necrosis, are covered in this review. Additionally, we provide an overview of four important clinical trials—DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER—highlighting their effectiveness in lowering unfavourable cardiovascular outcomes for patients with heart failure who have preserved (HFpEF), slightly reduced (HFmrEF), or reduced (HFrEF). The results validate the need for SGLT2 inhibitors in all-inclusive HF treatment plans by highlighting their adaptability and safety in a range of clinical contexts.
- 22 May 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 71, 49418
Open AccessSGLT2-Inhibitors - significant role in Heart Failure treatment
Heart failure (HF), which has a high morbidity and mortality rate, is nevertheless a common and crippling ailment, especially in older populations. The complicated pathophysiology of heart failure (HF), which includes oxidative stress, endothelial dysfunction, fibrosis, and inflammation, is frequently not sufficiently treated despite advances in medication. Inhibitors of the sodium-glucose co-transporter 2 (SGLT2) have become a key treatment for HF in patients with varying left ventricular ejection fractions (LVEF). SGLT2 inhibitors have been shown in recent clinical trials to considerably lower hospitalization rates for heart failure, cardiovascular mortality, and all-cause mortality. The mechanisms of SGLT2 inhibitors, such as better ventricular loading, increased heart metabolic efficiency, and decreased inflammation and necrosis, are covered in this review. Additionally, we provide an overview of four important clinical trials—DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER—highlighting their effectiveness in lowering unfavourable cardiovascular outcomes for patients with heart failure who have preserved (HFpEF), slightly reduced (HFmrEF), or reduced (HFrEF). The results validate the need for SGLT2 inhibitors in all-inclusive HF treatment plans by highlighting their adaptability and safety in a range of clinical contexts.
- Open Access
- 18 May 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 69, 49393
Lactase Deficiency and Lactose Intolerance: Current Understanding and Future Directions
Introduction and purpose: Lactose, the primary carbohydrate in milk, requires the enzyme lactase for digestion. Deficiency in lactase activity leads to lactose intolerance, causing gastrointestinal symptoms. Understanding the genetic and environmental factors influencing lactase expression and activity is crucial. Moreover, accurate diagnostic methods and effective treatments are needed to manage lactose intolerance. This review aims to explore the current knowledge on lactase deficiency, lactose intolerance, diagnostic methods, and treatment options. State of knowledge: Lactase deficiency encompasses congenital, primary, and secondary forms, each with distinct etiologies. Although often used interchangeably, lactase deficiency and lactose intolerance differ. However, the association between lactase deficiency and lactose intolerance is complex, influenced by various factors including dietary habits, gut microbiota, and gastrointestinal motility. Diagnostic methods are limited, and treatment strategies primarily involve dietary modifications, lactase supplementation, and probiotics. Conclusion: Lactose intolerance presents significant clinical challenges, often underrecognized and misdiagnosed. Despite diagnostic advancements further research is needed to refine diagnostic accuracy. Treatment focuses on dietary adjustments, enzyme supplementation, and probiotics. Balancing symptom relief with nutritional adequacy is essential. Future studies should explore the role of gut microbiome modulation in lactose intolerance management through clinical trials.
- 18 May 2024
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 69, 49393
Open AccessLactase Deficiency and Lactose Intolerance: Current Understanding and Future Directions
Introduction and purpose: Lactose, the primary carbohydrate in milk, requires the enzyme lactase for digestion. Deficiency in lactase activity leads to lactose intolerance, causing gastrointestinal symptoms. Understanding the genetic and environmental factors influencing lactase expression and activity is crucial. Moreover, accurate diagnostic methods and effective treatments are needed to manage lactose intolerance. This review aims to explore the current knowledge on lactase deficiency, lactose intolerance, diagnostic methods, and treatment options. State of knowledge: Lactase deficiency encompasses congenital, primary, and secondary forms, each with distinct etiologies. Although often used interchangeably, lactase deficiency and lactose intolerance differ. However, the association between lactase deficiency and lactose intolerance is complex, influenced by various factors including dietary habits, gut microbiota, and gastrointestinal motility. Diagnostic methods are limited, and treatment strategies primarily involve dietary modifications, lactase supplementation, and probiotics. Conclusion: Lactose intolerance presents significant clinical challenges, often underrecognized and misdiagnosed. Despite diagnostic advancements further research is needed to refine diagnostic accuracy. Treatment focuses on dietary adjustments, enzyme supplementation, and probiotics. Balancing symptom relief with nutritional adequacy is essential. Future studies should explore the role of gut microbiome modulation in lactose intolerance management through clinical trials.
- 29 April 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (2)
WILL ULTRASOUND REVOLUTIONIZE THE DIAGNOSIS OF PNEUMONIA IN CHILDREN POPULATION?
Worldwide, pneumonia continues to be a major cause of morbidity and mortality in children. The effectiveness of ultrasonography and chest radiography (X-ray) in the diagnosis of pneumonia in pediatric patients is examined in this paper. Although chest radiography has been the norm for years, worries about radiation exposure have made ultrasonography seem like a viable substitute. This article assesses both modalities' diagnostic value and accuracy through a review of recent literature. As a potentially useful diagnostic tool, ultrasonography has advantages over chest X-rays, including accessibility, low radiation dose, and similar diagnostic efficacy. Ultrasound has a high negative predictive value, which indicates that it may be used to efficiently triage patients in emergencies. The decision between an X-ray and an ultrasound ultimately comes down to several variables, such as patient condition, physician skill, and equipment accessibility. However, considering ultrasound's safety record and diagnostic capabilities, it offers a strong substitute for diagnosing pneumonia in kids, in line with WHO guidelines to reduce radiation exposure in this susceptible group.
- 29 April 2024
- Published by European Scientific Society in Archiv Euromedica
- Vol. 14 (2)
WILL ULTRASOUND REVOLUTIONIZE THE DIAGNOSIS OF PNEUMONIA IN CHILDREN POPULATION?
Worldwide, pneumonia continues to be a major cause of morbidity and mortality in children. The effectiveness of ultrasonography and chest radiography (X-ray) in the diagnosis of pneumonia in pediatric patients is examined in this paper. Although chest radiography has been the norm for years, worries about radiation exposure have made ultrasonography seem like a viable substitute. This article assesses both modalities' diagnostic value and accuracy through a review of recent literature. As a potentially useful diagnostic tool, ultrasonography has advantages over chest X-rays, including accessibility, low radiation dose, and similar diagnostic efficacy. Ultrasound has a high negative predictive value, which indicates that it may be used to efficiently triage patients in emergencies. The decision between an X-ray and an ultrasound ultimately comes down to several variables, such as patient condition, physician skill, and equipment accessibility. However, considering ultrasound's safety record and diagnostic capabilities, it offers a strong substitute for diagnosing pneumonia in kids, in line with WHO guidelines to reduce radiation exposure in this susceptible group.
- 30 June 2023
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 78 (8) , 964-965
Single coronary artery with retrosternal course
- 30 June 2023
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 78 (8) , 964-965
Single coronary artery with retrosternal course
- 15 June 2023
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 78 (7) , 1-2
Extracorporeal membrane oxygenation cannula in persistent left superior vena cava
- 15 June 2023
- Published by Taylor & Francis in Acta Cardiologica
- Vol. 78 (7) , 1-2
Extracorporeal membrane oxygenation cannula in persistent left superior vena cava